Navigation Links
Join NPR's David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Date:5/19/2008

GREENWICH, Conn., May 19 /PRNewswire/ -- Helix Health, the first U.S. stand-alone genomic medicine practice, is hosting a 90-minute webcast this Wednesday, May 21, 2008 from 1:00-2:30 PM EDT examining:
How Genomic Medicine Is Changing the Management of Breast & Ovarian Cancer

To register, point your browser here http://event.netbriefings.com/event/helixhealth/register.html .

Every hour, 150 people in the United States are diagnosed with cancer. There is a growing number of people who are not willing to wait for that diagnosis. They are undergoing genetic testing to discover, and to know what they must do to manage these risks... personalized medicine for effective heath care management.

Topics:

What should a doctor and patient do when a patient tests positive?

What is the risk in taking a "wait and see" approach?

Are there alternatives to radical surgery?

What are potential tort issues in predictive genetic testing and medical

uses of genetic tests?

Panel:

Steven A.R. Murphy, MD - Clinical Genetics Fellow at Yale School of

Medicine, and Helix Health's Managing Partner will moderate the panel.

Barbara A. Ward, MD - Director, The Breast Center of Greenwich Hospital;

principal investigator of the STAR Trial

http://www.ynhh.org/healthlink/cancer/cancer_7_99.html; surgical

oncologist affiliated with Yale-New Haven Health System.

Jessica Queller - author of Pretty Is What Changes; television writer for

Felicity, The Gilmore Girls and One Tree Hill. Writer/producer on Gossip

Girl.

Jennifer Ibrahim, MD - clinical geneticist specializing in preconception

genetics as well as familial cancer syndromes.

David Ewing Duncan - bestselling author of Masterminds: Genius, DNA and

the Quest to Rewrite Life; Director, Center for Life Sciences Policy, UC

Berkeley; Chief Correspondent and co-host of National Public Radio's

"Biotech Nation".

Gary E. Marchant - Ph.D. J.D., Lincoln Professor of Emerging

Technologies, Law & Ethics, Sandra Day O'Connor College of Law; Executive

Director, Center for Law, Science & Technology, Professor, School of Life

Sciences Arizona State University.

Registration

To register, point your browser here http://event.netbriefings.com/event/helixhealth/register.html

Registration is limited, so please register soon.

If you are unable to attend, a podcast of the session will soon be available on the Helix Health website. http://www.helixhealth.org/

About Helix Health, PLLC/LLC - a medical practice that is bringing genomic medicine to health care. With offices in Greenwich, CT and New York, NY, Helix Health offers patients and their physicians expertise in genomic medicine and provides the tools required to take full advantage of genetic testing.

Contact info@helixhealth.org for more information, or visit http://www.helixhealth.org/


'/>"/>
SOURCE Helix Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
5. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... 2017  Socionext Inc. and SOINN Inc. today ... in which Socionext extracts and delivers biometrics data ... initial results in reading ultrasound images from Socionext,s ... The results will be introduced at Medtec Japan, ... booths 4505 & 4507. In this ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... More than half of Americans suffering from ... in their leisure time that causes hearing loss? May 1 marks the beginning of ... to hearing loss, as well as schedule a hearing evaluation for anyone with concerns ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... Texas (PRWEB) , ... April 28, 2017 , ... The ... plaque in recently to the labor and delivery team at Women’s Hospital at Renaissance ... mothers who give birth at the hospital and decide to donate. , “Women’s ...
Breaking Medicine News(10 mins):